News
The day at a glance · 3 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Lilly AtaiBeckley Deal
$2.8B
AbbVie Apogee Deal
$10.9B
AbbVie 5-Year Return
172%
Key driverStrong earnings from UnitedHealth and M&A activity from Eli Lilly and AbbVie supporting sector momentum
Daily briefHealthcare· Money365.Market AI ·

Lilly, AbbVie Lead on M&A and European Approvals

UnitedHealth beats profit estimates; AbbVie secures two RINVOQ approvals in EU; Eli Lilly announces $2.8B acquisition

Big Pharma M&A and Pipeline Moves

Bullish
01LLY▲ +2.09%
Eli Lilly ($LLY) has announced the acquisition of AtaiBeckley for $2.8 billion, marking a significant entry into the psychedelics drug development space. The deal represents a strategic expansion for $LLY into an emerging therapeutic area, with investor Cathie Wood viewing alternative biotech names in the psychedelics sector as attractive opportunities. Separately, AbbVie ($ABBV) disclosed that it agreed to acquire Apogee Therapeutics for $10.9 billion to strengthen its immunology pipeline.
02ABBV
$ABBV stock has delivered 172% returns over five years, though current valuation metrics present a mixed picture with intrinsic value estimates suggesting upside while market multiples indicate the shares screen rich.

FDA and European Regulatory Approvals

Bullish

RINVOQ Alopecia Dose Range

15-30mg

RINVOQ Vitiligo Dose

15mg
01ABBV
AbbVie ($ABBV) announced that the European Commission has approved RINVOQ (upadacitinib) for two new indications in dermatology. The approvals cover treatment of adult and adolescent patients 12 years and older with severe alopecia areata at 15 mg and 30 mg once daily doses, as well as non-segmental vitiligo at 15 mg once daily. RINVOQ is now the first and only systemic medication approved in the European Union for non-segmental vitiligo, the most common form of vitiligo. These European approvals expand the commercial opportunity for $ABBV's key immunology franchise and can support expectations for future cash flows. Meanwhile, biotech company Replimune is engaged in discussions with regulators regarding approval for its first commercial product in combination with Bristol Myers Squibb's ($BMY) Opdivo.

Managed Care Earnings

Bullish

UnitedHealth Q2 Revenue

$112.03B

UnitedHealth Q2 Net Income

$5.48B

Healthcare Sector 6-Month

14.3%+14.3%
01UNH
UnitedHealth Group ($UNH) reported second-quarter 2026 results with revenue of $112.03 billion and net income of $5.48 billion, surpassing analyst expectations. The company raised its full-year profit outlook and continues executing share repurchases, highlighting how cost controls and capital returns are shaping its business profile. The earnings beat and outlook increase demonstrate $UNH's ability to manage medical costs while growing its diversified healthcare services businesses. Healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%, with companies innovating in drug development and digital health driving sector outperformance.

Healthcare Technology and AI Adoption

Bullish

AI Medical Coding 2026E

$3.4B

AI Medical Coding CAGR

13.5%

Precision Diagnostics CAGR

8.91%
01UNH
The global AI in medical coding market is projected to grow from approximately $3 billion in 2025 to $3.4 billion in 2026, reaching $10.6 billion by 2035 at a compound annual growth rate of 13.5%. Key market participants include 3M Company and Optum Inc., a UnitedHealth ($UNH) subsidiary, positioning the managed care giant to benefit from technology-driven efficiency gains in healthcare administration. Separately, the global precision diagnostics and medicine market is expected to expand from approximately $147.23 billion in 2025 to $159.66 billion in 2026, reaching $345.75 billion by 2035 at an 8.91% CAGR, with Thermo Fisher Scientific ($TMO) among the leading players.

Looking Ahead

Neutral

AbbVie Post-Breakout Gain

15%+15%
01AMGN
Amgen ($AMGN) will report second-quarter 2026 financial results on August 4, 2026, after the close of U.S. financial markets, followed by a conference call at 4:30 p.m. ET with chairman and CEO Robert A. Bradway and senior management.
02ABBV
AbbVie ($ABBV) faces an upcoming earnings report after the stock climbed 15% from its June 23 breakout above the 230.47 buy point from a cup-with-handle base, following the Apogee Therapeutics acquisition announcement that drove shares more than 6% higher.
03JNJ
Johnson & Johnson ($JNJ) has delivered strong Q2 earnings with record results and raised guidance, driven by its oncology engine and steady performance across business segments.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy